Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ADI 2016 | Potential new symptomatic drugs for Alzheimer’s disease

Serge Gauthier • 22 Apr 2016
ADI 2016
Alzheimer’s Disease Solanezumab

At the 31st International Conference of Alzheimer’s Disease International (ADI), held in Budapest, Hungary, from April 21–24 2016, Serge Gauthier, C.M., MD, FRCPC, from McGill Centre for Studies in Aging, McGill University, Montreal, Canada, reviews promising agents in clinical development for the symptomatic treatment of people with Alzheimer’s disease.

More from Serge Gauthier

1:09
Combination therapy for Alzheimer’s disease
Serge Gauthier • 22 Apr 2016

Related Videos

3:58
Promising FONLISA test for ultrasensitive detection of plasma NfL in Alzheimer’s disease
Madison Honey • 7 Mar 2024
4:12
Updates in Alzheimer’s treatment: the potential of NSC001
Manfred Windisch • 6 Mar 2024
4:44
Influence of genetic risk for psychiatric disorders on dementia
Jenna Najar • 6 Mar 2024
2:06
The role of governments in addressing the access issues to dementia treatment
Paola Barbarino • 23 Mar 2024
The content of VJDementia is intended for healthcare professionals